



▶ EMERGING POOL

Dr. Deborah **DUNSIRE**

ENVIVO PHARMACEUTICALS APPOINTS PRESIDENT AND CEO



EnVivo Pharmaceuticals, a privately held company working to convert its broad pipeline into a range of CNS therapies that leverage novel mechanisms of action by altering the progression of disease and providing improvement in cognitive and overall function, has named Deborah Dunsire, M.D., as president and CEO. She also joins the company's board of directors.

Dr. Dunsire, formerly president and CEO of Millennium: The Takeda Oncology Company, who brings more than 25 years of scientific, clinical, operational, and commercial experience, has proven leadership in the biological and pharmaceutical industry.

Before leading Millennium, Dr. Dunsire led the Novartis U.S. oncology business.

▶ SERVICE POOL

Justin **EDGE** Tom **NERI**

GfK APPOINTS NEW NORTH AMERICAN LEADERS IN HEALTH, FINANCIAL SERVICES



Strengthening its leadership in two core industries, GfK Consumer Experiences North America has named Justin Edge as managing director of health and Tom Neri as executive VP of financial services. They will head the North American client teams for these key areas of expertise.



Mr. Edge joined GfK in the 2012 acquisition of Knowledge Networks, where he led the pharmaceutical and health practice.

Before joining GfK in 2012, Mr. Neri was executive VP at Vision Critical, where he established and led the New York office.

Cheryle **EVANS**

ADVANCED CLINICAL NAMES VP, CLINICAL OPERATIONS



Advanced Clinical, a provider of clinical research solutions, has added Cheryle Evans, VP, clinical operations, to its leadership team. Ms. Evans is a tenured leader and will be responsible for strategic planning and tactile operations in project management, clinical monitoring, site activation, and document management.

▶ CRO POOL

Dr. Andrew **MONAGHAN**

CHILTERN APPOINTS DIRECTOR OF GLOBAL PHARMACOVIGILANCE



Chiltern International, a global contract research organization (CRO), has appointed Andrew Monaghan, Ph.D., as director, global pharmacovigilance.

In this role, Dr. Monaghan leads the Chiltern pharmacovigilance team and is expected to expand the organization's global pharmacovigilance offering.

He has more than 30 years of experience in clinical research and development among top pharmaceutical companies, most recently as global head of safety operations at Roche Products, UK, where he led and managed 500 safety operations staff across seven locations globally and delivered the business safety compliance goals.

▶ AGENCY POOL

Jigna **BARANELLO** David **DANILOWICZ** Hsiao **LIU** Gabriela **MADERA**

OGILVY COMMONHEALTH WORLDWIDE PROMOTES TWO AND HIRES THREE



Ogilvy CommonHealth Worldwide, the health behavior experts of Ogilvy & Mather, has made several promotions and new hires at the organization's New York and New Jersey offices.



Jigna Baranello returns to Ogilvy CommonHealth Worldwide as VP, account group supervisor, for the company's specialty marketing group. Most recently, she was employed at Solstice HealthCommunications.



David Danilowicz joins Ogilvy CommonHealth Worldwide as senior VP, chief innovation officer, at the organization's Parsippany, N.J., office. Mr. Danilowicz is responsible for overseeing digital capabilities and creative resources for his department and its projects.



Hsiao Liu rejoins the Ogilvy CommonHealth Worldwide network as senior VP, regional business lead, at Ogilvy Healthworld in New York. Previously, Ms. Liu served as the emerging market Asia regional therapeutic area lead at Pfizer.

Gabriela Madera, who is with Ogilvy CommonHealth Worldwide's Medical Marketing group, has advanced from senior account executive, to account supervisor after five years. Ms. Madera's new position entails defining clients' business objectives while providing strategic and tactical recommendations and overseeing her assigned projects to ensure clients' expectations are achieved.

Richard **CAMPBELL** Sonja **FOSTER-STORCH** Bill **MCELLEN** Marci **PIASECKI** Maureen **REGAN** Brendan **WARD** Kim **WISHNOW-PER**

MCCANN HEALTH ANNOUNCES MAJOR LEADERSHIP PROMOTIONS FOR NORTH AMERICAN MANAGEMENT

McCann Health has made a series of major moves aimed at bolstering the capabilities of its North American operations.

Bill McEllen has been promoted to president of McCann Torre Lazur Group, overseeing McCann Torre Lazur and McCann Echo Torre Lazur. Mr. McEllen had been president of Echo Torre Lazur.

Succeeding Mr. McEllen as president of McCann Echo Torre Lazur is Sonja Foster-Storch, formerly managing director of CDM Princeton.



Marci Piasecki has been named to the newly created position of regional director of McCann Health North America. Previously, Ms. Piasecki was CEO of McCann Torre Lazur Group. Her

new regional management responsibilities include overseeing McCann Torre Lazur, McCann Echo Torre Lazur, McCann Regan Campbell Ward, McCann RCW Healthcare, and McCann Managed Markets.

Maureen Regan retains her leadership role at McCann Regan Campbell Ward Group, consisting of McCann Regan Campbell Ward and McCann RCW Healthcare, as president, while Brendan Ward evolves in to a complex science role for the agency, and Richard Campbell retains his role as head of planning.

Kim Wishnow-Per has been named president of McCann Managed Markets, previously known as McCann Torre Lazur Managed Markets; she and the managed markets agency now partner across all McCann Health U.S. agencies under the same governance.

Kristen **DIMMOCK** Anthony **HALL**

DUDNYK MAKES MOVES IN WEST COAST

Kristen Dimmock, an experienced professional



who has led accounts in the United States and abroad, joins Dudnyk West as account supervisor.

Anthony Hall has joined Dudnyk West, San Francisco, as creative director, digital. With a wealth of expertise in UX, design, development, and QA, Mr. Hall takes on responsibility for the San Francisco agency's digital offerings.

Dr. Michelle DOCKHORN

SCORR MARKETING ADDS TO EXECUTIVE TEAM

Michelle Dockhorn, Ph.D., an executive with extensive marketing and business development leadership experience specific to the life-science industry, has joined Scorr Marketing, a full-service marketing and communications firm, as VP of global markets.



Tina FASCETTI

ROSKA HEALTHCARE NAMES EXECUTIVE VP/CHIEF CREATIVE OFFICER

Tina Fascetti has joined Roska Healthcare Advertising as executive VP and chief creative officer.

Ms. Fascetti previously worked with Roska as a consultant on several critical projects, and brings to her new role more

than 20 years of experience managing agency-of-record relationships, product launches, customer experience programs, and branding initiatives in the pharmaceutical and consumer industry.

ASSOCIATION POOL

Barbara Lopez KUNZ

DIA NAMES GLOBAL CHIEF EXECUTIVE



Barbara Lopez Kunz has been named global chief executive of the Drug Information Association (DIA), a global, professional and member-driven association of almost 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and related healthcare products.

Ms. Kunz was formerly president of the global health and life sciences business at Battelle, an international science and technology nonprofit organization.

A leader on numerous corporate and nonprofit boards, she has presided over the board of The Ohio State University Wexner Medical Center and is a trustee of both the Nationwide Children's Hospital research institute and BioOhio, the statewide organization stimulating economic development in the bioscience community.

TECHNOLOGY POOL

Jeff HUGGINS

INTOUCH SOLUTIONS HIRES SENIOR TECHNOLOGY STRATEGIST



Jeff Huggins has joined Intouch Solutions, a digital agency, as its new senior technology strategist.

Mr. Huggins joins the technology strategist team at Intouch Solutions, overseeing the development of new technology solutions for clients and ensuring the organization remains on the leading edge of new advancements, protocols, and regulations affecting the industry. Previously, he served as senior VP at MMGY Global.

Steve ROSENBERG

PHT NAMES CHIEF OPERATING OFFICER



PHT Corp., a provider of innovative technology systems used to collect patient-driven eData for clinical research, has named Steven Rosenberg chief operating officer. He has responsibility for all aspects of product development, product management, and service delivery.

He was previously VP of software and services, health sciences global business unit, at Oracle.



USE YOUR QR CODE READER
OR GO TO
bit.ly/PV0913-TalentPool



Gain industry insight and excel in your pharmaceutical digital strategy at DigiPharm & Mobile Pharma Europe

8 - 10 October 2013, London, UK

Attend DigiPharm & Mobile Pharma Europe to understand: Multi channel marketing strategy, Digital integration and implementation, Customer engagement, Regulatory compliance, Sales force integration, Mobile technologies

Hear from the outstanding industry speaker panel, including:

Ragnar Gåseby, Executive Director, Global Head, Multi Channel Marketing, **Merck**

Philippe Barillon, Head Customer and Market Insights Europe, **Teva**

Michel Baes, Vice President, EMEA Customer Orientation and Innovation, **Janssen**

Peter Aksel Villadsen, Director, Global Patient Engagement, **Leo Pharma**

Scott Curley, Global Digital Engagement & Capability Director, **AstraZeneca**

Book now to secure your place.
Enter promotion code: PVHP
to receive the best price



Book now and get the best price
- on your phone

Scan this QR pattern with the camera on your smartphone to register at the special offer price.

Don't have a smartphone? You can also register and get the offer on our website: www.healthnetworkcommunications.com/digipharm - quote voucher code PVHP

DigiPharm
Europe 2013
Mobile Pharma
World EUROPE 2013

www.healthnetworkcommunications.com/digipharm

► **PHARMA POOL****Dr. Steven CAFFE****AMAG PHARMACEUTICALS APPOINTS CHIEF DEVELOPMENT AND REGULATORY OFFICER**

AMAG Pharmaceuticals, a specialty pharmaceutical company, has appointed Steven Caffe, M.D., as senior VP and chief development and regulatory officer. Dr. Caffe brings 20 years of experience in global biopharmaceuticals development and regulatory approvals to AMAG. He joins AMAG from MedImmune, AstraZeneca's global biologics research and development arm, where he most recently served as senior VP of global regulatory affairs and patient safety.

Roger GRAHAM**MYLAN SPECIALTY NAMES PRESIDENT**

Mylan Inc., a global pharmaceutical company, has appointed Roger Graham president of Mylan Specialty.

Mr. Graham joins Mylan from Advandx, a private developer of in-vitro diagnostic tests in the infectious disease space. He was the company's chief commercial officer and developed its growth strategy for the U.S. and European markets.

► **BIOTECH POOL****Paul PERREAULT****CSL LIMITED NAMES CEO**

Paul Perreault assumes the role of CEO and managing director of CSL Ltd., a global specialty biopharmaceuticals company that delivers innovative, lifesaving and life-enhancing therapies to meet the critical needs of people with rare and serious diseases.

Mr. Perreault has more than 30 years of experience in the healthcare and biopharmaceutical industry. During his tenure at Aventis Behring, he held leadership positions in sales, marketing and operations.

► **BIOPHARMA POOL****Dr. Theodore DANOFF****Dr. Wael SALAMEH****CLARUS THERAPEUTICS BOLSTERS EXECUTIVE TEAM**

Clarus Therapeutics has hired Theodore Danoff, M.D., Ph.D., and Wael Salameh, M.D., to fill the newly created posts of VP, clinical development and chief medical officer, and VP, medical affairs and chief scientific officer.

Dr. Danoff has been board certified in internal medicine and nephrology and has extensive pharmaceutical industry R&D experience at SmithKline Beecham, GlaxoSmithKline and, most recently, Endo Pharmaceuticals where he was VP, clinical development and medical affairs.

Dr. Salameh is board certified in internal medicine and endocrinology and has specialized training in andrology/men's health. Before joining Clarus, Dr. Salameh was on the medical faculties of Temple University and UCLA.

Dr. Robert JANSSEN**DYNAXX NAMES CHIEF MEDICAL OFFICER**

Dynavax Technologies has appointed Robert Janssen, M.D., as chief medical officer and VP, clinical development. Dr. Janssen most recently served as Dynavax's VP, medical affairs, and was previously senior director, clinical development.

Dr. Neil SCHAUER**AVAXIA BIOLOGICS APPOINTS VP, TECHNICAL OPERATIONS**

Avaxia Biologics, a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, has named Neil Schauer, Ph.D., VP, technical operations. In this newly created position, Dr. Schauer has responsibility for process development, manufacturing, formulation, and quality for the entire Avaxia product candidate pipeline.

Dr. Schauer is an executive-level leader and scientist with more than 25 years of experience in the development and manufacture of biologic therapeutics. Most recently, he held the position of VP, process sciences, Inspiration Biopharmaceuticals.

Dr. Karen TUBRIDY**ELEVEN BIOTHERAPEUTICS APPOINTS CHIEF DEVELOPMENT OFFICER**

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, has appointed biologics industry veteran Karen Tubridy, Pharm.D., as chief development officer.

She is responsible for leading and executing the company's clinical and regulatory development strategy, currently focused on innovative protein therapeutics for ocular diseases.

Most recently, she served as senior VP, clinical development and medical affairs, at Inspiration Biopharmaceuticals.

► **EMERGING POOL****Peter GREENLEAF****HISTOGENICS APPOINTS CEO**

Peter Greenleaf, former president of MedImmune, the worldwide biologics arm of AstraZeneca, has been appointed CEO of Histogenics.

Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration.

► **DRUG DELIVERY POOL****Dr. Peter NOYMER****Rick WHITE****STEADYMED THERAPEUTICS ADDS TO EXECUTIVE TEAM**

SteadyMed Therapeutics, a private drug delivery therapeutics company, has named Peter Noymer, Ph.D., executive VP of R&D and chief technology officer, and Rick White as VP of business development and commercial operations.

Dr. Noymer is responsible for completing the development of the company's PatchPump parenteral drug delivery technology as well as leading clinical and regulatory affairs for SteadyMed's PatchPump drug product to treat pulmonary arterial hypertension (PAH).

Previously, he was VP of product R&D at Alexza Pharmaceuticals.

Mr. White is responsible for both business development activities related to the licensing of the PatchPump technology as well as the initiation of precommercial activities relating to the PatchPump drug product to treat PAH.

► **SERVICE POOL****Renée BELL****NEUROVATIONS NAMES DIRECTOR OF CLINICAL RESEARCH**

Renée Bell joins Neurovations, a clinical research and consulting company in the fields of pain man-

agement and neuroscience, as director of clinical research.

Responsible for managing the clinical research operation at Neurovations, she is working alongside clinical education staff to develop mutual synergies with more than 25 client companies, including early stage and industry leading firms.

Maria GALDOS

QPHARMA APPOINTS SENIOR MANAGER, HEALTHCARE COMPLIANCE

QPharma, a regulatory consulting and brand solutions firm for the life-sciences industry, has appointed Maria Galdos to the position of senior manager, healthcare compliance.

Ms. Galdos specializes in helping pharmaceutical, medical device, and other life-sciences organizations establish and maintain full compliance with rules and guidance enacted by state and federal regulatory authorities, including the FDA and the Centers for Medicare and Medicaid Services (CMS).

► CRO POOL

Andrea CRACRAFT

PSI NAMES DIRECTOR CLINICAL OPERATIONS NORTH AMERICA

PSI CRO, a full-service contract research organization, has appointed Andrea Cracraft as director, clinical operations North America.

Ms. Cracraft has more than 15 years of experience in clinical research and joins PSI after spending eight years in various senior roles with another global CRO. She brings a depth of pharmaceutical expertise in running global projects in various therapeutic areas, including oncology, respiratory, CNS, musculoskeletal, cardiovascular, and genitourinary.

Dr. Arthur TIPTON

SOUTHERN RESEARCH INSTITUTE NAMES PRESIDENT AND CEO

Southern Research Institute, a nonprofit scientific research organization, has named Arthur Tipton, Ph.D., as president and CEO.

Dr. Tipton replaces John A. "Jack" Secrist, III, Ph.D., who served as president and CEO of Southern Research Institute for seven years. Dr. Secrist announced his retirement earlier this year after 34 years of service at Southern Research.

Dr. Tipton previously served as senior VP and general manager of Evonik — Birmingham Laboratories.

► TECHNOLOGY POOL

Dr. Kuno VAN DER POST

OMNICOMM SYSTEMS APPOINTS SENIOR VP OF BUSINESS DEVELOPMENT

OmniComm Systems, which specializes in EDC, has promoted Kuno van der Post, Ph.D., to senior VP of business development. Dr. van der Post was most recently OmniComm's VP of business development, managing the Southeast region of the U.S. His new duties include overseeing all of OmniComm's global sales and marketing responsibilities. **PV**

CMO SUMMIT WEST



THE FIRST WEST COAST EVENT ADDRESSING THE COMPLEX DUAL ROLE OF MANAGING R&D WHILE RAISING CAPITAL FOR BIOTECHS

NOVEMBER 4 - 5, 2013

MARINES' MEMORIAL HOTEL, SAN FRANCISCO, CA

CO-CHAIR: REGULATORY STRATEGY



Lee Allen, MD, PhD
CMO
Spectrum
Pharmaceuticals

CO-CHAIR: RESOURCEFUL OUTSOURCING



Sheila Gujrathi, MD
CMO
Receptos

THE CMO'S ROLE IN RAISING CAPITAL



Srinivas Akkaraju, MD, PhD
General Partner
Sofinnova Ventures

THE REALITY OF THE CMO ROLE



Tyler Martin, MD
Founder, CEO & CMO
Great Plains
Biotechnology

BEST PRACTICES ON DAY ONE:

Clinical Development/Outsourcing & Regulatory Management in the Emerging Life Science Space

BEST PRACTICES ON DAY TWO:

Investment Strategies, Exit Planning & Trends that will Change the Funding of Medical Research in the Emerging Life Science Space

DESIGNED FOR:

- ✓ Chief Medical Officers, Heads of R&D/Clinical Operations, Chief Scientific Officers
- ✓ Life Science Investors, Government Sources of Capital & Passion/Patient Capital

Organized by



15% DISCOUNT WITH CODE PV15

Media Partner



TO REGISTER, VISIT WWW.THECONFERENCEFORUM.ORG OR CALL 646-350-2580